#BEGIN_DRUGCARD DB01026

# AHFS_Codes:
08:14.08
84:04.08.08

# ATC_Codes:
D01AC08
G01AF11
J02AB02

# Absorption:
Moderate

# Biotransformation:
Hepatic

# Brand_Mixtures:
Not Available

# Brand_Names:
Extina
Fungarest
Fungoral
Ketoderm
Ketoisdin
Ketozole
Nizoral
Nizoral Cream
Nizoral Shampoo
Nizoral a-D
Nizoral a-D Shampoo
Orifungal
Orifungal M
Panfungol
Sebazole

# CAS_Registry_Number:
65277-42-1

# ChEBI_ID:
48339

# Chemical_Formula:
C26H28Cl2N4O4

# Chemical_IUPAC_Name:
1-[4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]ethan-1-one

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
2237235

# Description:
Broad spectrum antifungal agent used for long periods at high doses, especially in immunosuppressed patients. [PubChem]

# Dosage_Forms:
Cream	Topical
Shampoo	Topical
Tablet	Oral

# Drug_Category:
Antifungal Agents
Antifungals

# Drug_Interactions:
Abiraterone 	Strong CYP3A4 inhibitors may increase levels of abiraterone. Monitor concomitant therapy closely.
Acenocoumarol	Ketoconazole may increase the anticoagulant effect of acenocoumarol.
Alfentanil	Ketoconazole may increase the effect and toxicity of alfentanil.
Alfuzosin	The antifungal increases the effect of alfuzosin
Almotriptan	This potent CYP3A4 inhibitor increases the effect and toxicity of the triptan
Alprazolam	Ketoconazole may increase the effect of the benzodiazepine, alprazolam.
Aluminium	Aluminum-containing antacids may decrease the effect of ketoconazole.
Amitriptyline	Ketoconazole, a moderate CYP2D6 inhibitor,  may increase the serum concentration of amitriptyline by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amitriptyline if ketoconazole is initiated, discontinued or dose changed.
Anisindione	Ketoconazole may increase the anticoagulant effect of anisindione.
Apixaban	Avoid combination. Otherwise, ketoconazole will likely increase apixaban serum concentration.
Aprepitant	This CYP3A4 inhibitor increases the effect and toxicity of aprepitant
Aripiprazole	Ketoconazole may increase the effect of aripiprazole.
Artemether	Concurrent oral administration of ketoconazole, a potent CYP3A4 inhibitor, with a single dose of Coartem Tablets resulted in a moderate increase in exposure to artemether, DHA, and lumefantrine in a study of 15 healthy subjects.
Astemizole	Increased risk of cardiotoxicity and arrhythmias
Atorvastatin	Increased risk of myopathy/rhabdomyolysis
Avanafil	Co-administration with the strong CYP3A4 inhibitor ketoconazole resulted in an approximate 13-fold increase in AUC0-inf and 3.1-fold increase in Cmax.
Bedaquiline	Strong CYP3A4 inhibitors may increase exposure of bedaquiline. Monitor concomitant therapy closely.
Bosentan	Ketoconazole may increase the effect and toxicity of bosentan.
Bosutinib	Strong CYP3A4 inhibitors may increase levels of bosutinib. Monitor concomitant therapy closely.
Bromazepam	Ketoconazole may increase the serum concentration of bromazepam by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of bromazepam if ketoconazole is initiated, discontinued or dose changed.
Budesonide	Ketoconazole may increase levels/effect of budesonide.
Cabazitaxel	Concomitant therapy with a strong CYP3A4 inhibitor may increase concentrations of cabazitaxel. Avoid concomitant therapy.
Calcium	Calcium-containing antacids may decrease the absorption of ketoconazole.
Carbamazepine	Ketoconazole may increase the effect of carbamazepine.
Cerivastatin	Increased risk of myopathy/rhabdomyolysis
Chlordiazepoxide	Ketoconazole may increase the effect of the benzodiazepine, chlordiazepoxide.
Ciclesonide	Increased effects/toxicity of ciclesonide
Cilostazol	Ketoconazole may increase the effect of cilostazol.
Cimetidine	The H2-receptor antagonist, cimetidine, may decrease the absorption of ketoconazole.
Cinacalcet	Ketoconazole may increase the effect and toxicity of cinacalcet.
Cisapride	Increased risk of cardiotoxicity and arrhythmias
Clobazam	Clobazam may increase levels by affecting CYP2C19 metabolism. Interaction is significant so monitor closely. Dose adjustment may be necessary.
Clonazepam	Ketoconazole may increase the effect of the benzodiazepine, clonazepam.
Clorazepate	Ketoconazole may increase the effect of the benzodiazepine, clorazepate.
Conivaptan	Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Conivaptan. Concomitant use of conivaptan with strong CYP3A4 inhibitors (e.g., azole antifungals) is contraindicated.
Crizotinib	Strong CYP3A4 inhibitors may increase levels of crizotinib. Monitor concomitant therapy closely.
Cyclosporine	Ketoconazole may increase the effect of cyclosporine.
Dabigatran etexilate	Coadministration with a strong p-glycoprotein inhibitor may increase the level or effect of dabigatran. Monitor closely for adverse effects.
Dantrolene	Ketoconazole may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if ketoconazole is initiated, discontinued or dose changed.
Darifenacin	This potent CYP3A4 inhibitor slows darifenacin/solifenacin metabolism
Diazepam	Ketoconazole may increase the effect of the benzodiazepine, diazepam.
Dicumarol	Ketoconazole may increase the anticoagulant effect of dicumarol.
Dihydroergotamine	Possible ergotism and severe ischemia with this combination
Docetaxel	Ketoconazole may increase the serum levels and toxicity of docetaxel.
Dofetilide	This strong CYP3A4 inhibitor increases the effect and toxicity of dofetilide
Dronedarone	Ketoconazole is a strong CYP3A4 inhibitor in which concomitant use with dronedarone will significantly increase its exposure. Avoid concomitant use.
Eletriptan	This potent CYP3A4 inhibitor increases the effect and toxicity of the triptan
Eplerenone	Ketoconazole, a CYP3A4 inhibitor, may increase the effect and toxicity of eplerenone.
Ergotamine	Possible ergotism and severe ischemia with this combination.
Erlotinib	This CYP3A4 inhibitor increases levels/toxicity of erlotinib
Esomeprazole	The proton pump inhibitor, esomeprazole, may decrease the absorption of ketoconazole.
Estazolam	Ketoconazole may increase the effect of the benzodiazepine, estazolam.
Ethinyl Estradiol	This anti-infectious agent could decrease the effect of the oral contraceptive
Etravirine	Etravirine, when used concomitantly with Ketoconazole (and other azole derivatives), may experience an increase in serum concentration.

Ketoconazole (and other azole derivatives), when used concomitantly with etravirine, may experience a decrease in serum concentration.

It is recommended to monitor etravirine therapy for toxicity.
Everolimus	Ketoconazole may increase everolimus levels/toxicity.
Famotidine	The H2-receptor antagonist, famotidine, may decrease the absorption of ketoconazole.
Fentanyl	Ketoconazole may increase levels/toxicity of fentanyl.
Fesoterodine	Ketoconazole is a potent CYP3A4 inhibitor thus reducing clearance. Avoid concomitant use with fesoterodine.
Fingolimod	Exposure is increased by 70% during concomitant use with systemic ketoconazole, and risk of adverse reactions is greater.
Flurazepam	Ketoconazole may increase the effect of the benzodiazepine, flurazepam.
Fluticasone furoate 	Strong CYP3A4 inhibitors may increase levels of fluticasone furoate. Monitor concomitant therapy closely.
Galantamine	Ketoconazole increases the effect and toxicity of galantamine
Gefitinib	This CYP3A4 inhibitor increases levels/toxicity of gefitinib
Glimepiride	Ketoconazole increases the effect of rosiglitazone
Halazepam	Ketoconazole may increase the effect of the benzodiazepine, halazepam.
Haloperidol	Ketoconazole may increase the effect and toxicity of haloperidol.
Iloperidone	Ketoconazole is a strong CYP3A4 inhibitor that increases serum concentration of iloperidone and likelihood of observing adverse effects such as QT prolongation. Reduce dose of iloperidone by 50%
Imatinib	Ketoconazole may increase the levels of imatinib.
Imipramine	Ketoconazole, a moderate CYP2D6 inhibitor,  may increase the serum concentration of imipramine by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of imipramine if ketoconazole is initiated, discontinued or dose changed.
Indacaterol	Strong CYP3A4 inhibitors increase levels of indacaterol. Consider alternate therapy.
Indinavir	Indinavir may increase the serum concentration of ketoconazole. Ketoconazole may increase the serum concentration of indinavir. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if either agent is initiated, discontinued or dose changed.
Irinotecan	Ketoconazole increases the effect and toxicity of irinotecan
Isoniazid	Isoniazid decreases the effect of ketoconazole
Ivacaftor	Strong CYP3A4 inhibitors may increase levels of ivacaftor. Monitor concomitant therapy closely.
Lansoprazole	The proton pump inhibitor, lansoprazole, may decrease the absorption of ketoconazole.
Lovastatin	Increased risk of myopathy/rhabdomyolysis
Lurasidone	Concomitant therapy with a strong CYP3A4 inhibitor will increase level or effect of lurasidone. Coadministration with lurasidone is contraindicated.
Magnesium oxide	The antacid, magnesium oxide, may decrease the effect of ketoconazole by decreasing its absorption.
Mestranol	This anti-infectious agent could decrease the effect of the oral contraceptive
Methylprednisolone	The imidazole, ketoconazole, may increase the effect and toxicity of the corticosteroid, methylprednisolone.
Midazolam	Ketoconazole may increase the effect of the benzodiazepine, midazolam.
Mirabegron 	Concomitant therapy with p-glycoprotein and strong CYP3A4 inhibitors may increase levels of mirabegron. Monitor concomitant therapy closely.
Nevirapine	Nevirapine, a strong CYP3A4 inducer, may decrease the serum concentration of ketoconazole by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of ketoconazole if nevirapine is initiated, discontinued or dose changed.
Nizatidine	The H2-receptor antagonist, nizatidine, may decrease the absorption of ketoconazole.
Nortriptyline	Ketoconazole, a moderate CYP2D6 inhibitor,  may increase the serum concentration of nortriptyline by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nortriptyline if ketoconazole is initiated, discontinued or dose changed.
Omeprazole	The proton pump inhibitor, omeprazole, may decrease the absorption of ketoconazole.
Ospemifene	Ketoconazole, a strong CYP3A4 inhibitor increases the systemic exposure of ospemifene by 1.4-fold. Administration of ketoconazole chronically with ospemifene may increase the risk of OSPHENA-related adverse reactions.
Pantoprazole	The proton pump inhibitor, pantoprazole, may decrease the absorption of ketoconazole.
Pazopanib	Ketoconazole is a strong inhibitor of CYP3A4 thus increasing exposure of pazopanib by 120% in healthy subjects.
Pimozide	Increased risk of cardiotoxicity and arrhythmias
Pioglitazone	Ketoconazole increases the effect of pioglitazone
Pomalidomide	Strong CYP3A4 inhibitors may increase levels of pomalidomide. Concomitant therapy should be avoided.
Ponatinib 	Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely.
Prasugrel	Ketoconazole is a potent inhibitor of CYP3A4 which decreases the Cmax of prasugrel due to a reduction of prasugrel bioactivation. However, there was no reduction of inhibition of platelet aggregation.
Prednisolone	The imidazole, ketoconazole, may increase the effect and toxicity of the corticosteroid, prednisolone.
Prednisone	The imidazole, ketoconazole, may increase the effect and toxicity of the corticosteroid, prednisone.
Quazepam	Ketoconazole may increase the effect of the benzodiazepine, quazepam.
Quetiapine	Ketoconazole may increase the therapeutic and adverse effects of quetiapine.
Quinidine	Ketoconazole may increase the effect and toxicity of quinidine.
Quinidine barbiturate	Ketoconazole may increase the effect and toxicity of quinidine barbiturate.
Rabeprazole	The proton pump inhibitor, rabeprazole, may decrease the absorption of ketoconazole.
Ramelteon	Ketoconazole may increase the serum levels and toxicity of ramelteon.
Ranitidine	The H2-receptor antagonist, ranitidine, may decrease the absorption of ketoconazole.
Ranolazine	Increased levels of ranolazine - risk of toxicity
Regorafenib	Strong CYP3A4 inhibitors may increase levels of regorafenib.
Rifampin	Rifampin may decrease the effect of ketoconazole.
Ritonavir	Ketoconazole may increase the effect and toxicity of ritonavir.
Rivaroxaban	Use of rivaroxaban with agents that are strong inhibitors of both CYP3A4 and P-glycoproteins are contraindicated.
Roflumilast	Increases roflumilast levels.
Rosiglitazone	Ketoconazole increases the effect of rosiglitazone
Ruxolitinib	Strong CYP3A4 inhibitors may increase levels of ruxolitinib. Consider alternate therapy.
Saquinavir	Ketoconazole may increase the effect and toxicity of saquinavir.
Saxagliptin	Ketoconazole is a strong inhibitor of CYP3A4/5 which increases exposure of saxagliptin. The exposure of the active metabolite, 5-hydroxy saxagliptin, also decreases. Decrease dose of saxagliptin to 2.5 mg per day.
Sibutramine	Ketoconazole increases the levels and toxicity of sibutramine
Sildenafil	Ketoconazole may increase the effect and toxicity of sildenafil.
Silodosin	Ketoconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of silodosin by decreasing its metabolism thus increases the potential for adverse side effects
Simvastatin	Increased risk of myopathy/rhabdomyolysis
Sirolimus	Ketoconazole may increase the effect and toxicity of sirolimus.
Solifenacin	This potent CYP3A4 inhibitor slows darifenacin/solifenacin metabolism
Sucralfate	Sucralfate may decrease the absorption of ketoconazole.
Sunitinib	Possible increase in sunitinib levels
Tacrine	The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by strong CYP1A2 inhibitors such as Ketoconazole. Consider modifying therapy to avoid Tacrine toxicity. Monitor the efficacy and toxicity of Tacrine if Ketoconazole is initiated, discontinued or if the dose is changed.
Tacrolimus	The antifungal, Ketoconazole, may increase serum concentrations of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Ketoconzole therapy is initiated, discontinued or altered.
Tadalafil	Ketoconazole may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity.
Tamoxifen	Ketoconazole may increase the serum concentration of Tamoxifen by decreasing its metabolism and clearance. Ketoconazole may also decrease the therapeutic effect of Tamoxifen by decreasing active metabolite production. Monitor for changes in the therapeutic/adverse effects of Tamoxifen if Ketoconazole is initiated, discontinued or dose changed.
Tamsulosin	Ketoconazole, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Ketoconzole is initiated, discontinued, or dose changed.
Telaprevir	Strong CYP3A4 inhibitors increase exposure of telaprevir.
Telithromycin	Ketoconazole may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects.
Temsirolimus	Ketoconazole may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided.
Teniposide	The strong CYP3A4 inhibitor, Ketoconazole, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Ketoconazole is initiated, discontinued or dose changed.
Terfenadine	Increased risk of cardiotoxicity and arrhythmias
Thiothixene	The strong CYP1A2 inhibitor, Ketoconazole, may decrease the metabolism and clearance of Thiothixene, a CYP1A2 substrate. Consider alternate therapy or monitor for changes in Thiothixene therapeutic and adverse effects if Ketoconazole is initiated, discontinued or dose changed.
Tiagabine	The strong CYP3A4 inhibitor, Ketoconazole, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Ketoconazole is initiated, discontinued or dose changed.
Tipranavir	Tipranavir may increase the serum concentration of Ketoconazole.
Tizanidine	Ketoconazole may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration.
Tolbutamide	Ketoconazole, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Ketoconazole is initiated, discontinued or dose changed.
Tolterodine	Ketoconazole may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
Tolvaptan	Ketoconazole is a strong inhibitor of CYP3A4 and will increase serum concentrations of tolvaptan by 82%.
Topotecan	The p-glycoprotein inhibitor, Ketoconazole, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided.
Torasemide	Ketoconazole, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Ketoconazole is initiated, discontinued or dose changed.
Tramadol	Ketoconazole may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Ketoconazole may decrease the effect of Tramadol by decreasing active metabolite production.
Trazodone	The CYP3A4 inhibitor, Ketoconazole, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Ketoconazole is initiated, discontinued or dose changed.
Triazolam	Ketoconazole may increase the effect of the benzodiazepine, triazolam.
Trimethoprim	The strong CYP2C9 inhibitor, Ketoconazole, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Ketoconazole is initiated, discontinued or dose changed.
Trimipramine	The strong CYP3A4 inhibitor, Ketoconazole, may decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Ketoconazole is initiated, discontinued or dose changed.
Ulipristal 	Concomitant therapy with strong CYP3A4 inhibitors may increase plasma concentrations of ulipristal. Avoid combination therapy.
Valdecoxib	Ketoconazole may increase the effect and toxicity of valdecoxib.
Vardenafil	Ketoconazole, a potent CYP3A4 inhibitor, may decrease the metabolism and clearance of Vardenafil. Concomitant therapy is contraindicated.
Vemurafenib	Strong CYP3A4 inhibitors may increase levels of vemurafenib. Monitor concomitant therapy closely.
Venlafaxine	Ketoconazole, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Ketoconazole is initiated, discontinued, or dose changed.
Verapamil	Ketoconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Ketoconazole is initiated, discontinued or dose changed.
Vilazodone	CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone. imit maximum adult vilazodone dose to 20 mg/day in patients receiving strong CYP3A4 inhibitors.
Vinblastine	Ketoconazole, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Ketoconazole is initiated, discontinued or dose changed.
Vincristine	Ketoconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Ketoconazole is initiated, discontinued or dose changed.
Vinorelbine	Ketoconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Ketoconazole is initiated, discontinued or dose changed.
Voriconazole	Ketoconazole, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if ketoconazole is initiated, discontinued or dose changed.
Warfarin	Ketoconazole, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if ketoconazole is initiated, discontinued or dose changed.
Zafirlukast	Ketoconazole, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if ketoconazole is initiated, discontinued or dose changed.
Ziprasidone	Ketoconazole increases the effect and toxicity of ziprasidone
Zolpidem	Ketoconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if ketoconazole is initiated, discontinued or dose changed.
Zonisamide	Ketonconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if ketoconazole is initiated, discontinued or dose changed.
Zopiclone	Ketonconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if ketoconazole is initiated, discontinued or dose changed.

# Drug_Reference:
10451809	Berwaerts J, Verhelst J, Mahler C, Abs R: Cushing's syndrome in pregnancy treated by ketoconazole: case report and review of the literature. Gynecol Endocrinol. 1999 Jun;13(3):175-82.
10933341	Goeders NE, Peltier RL, Guerin GF: Ketoconazole reduces low dose cocaine self-administration in rats. Drug Alcohol Depend. 1998 Dec 1;53(1):67-77.
12476017	Pierard-Franchimont C, Goffin V, Decroix J, Pierard GE: A multicenter randomized trial of ketoconazole 2% and zinc pyrithione 1% shampoos in severe dandruff and seborrheic dermatitis. Skin Pharmacol Appl Skin Physiol. 2002 Nov-Dec;15(6):434-41.
15737124	Kazy Z, Puho E, Czeizel AE: Population-based case-control study of oral ketoconazole treatment for birth outcomes. Congenit Anom (Kyoto). 2005 Mar;45(1):5-8.

# Drug_Type:
Approved
Investigational
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
4.35

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
0.0866 mg/L

# Food_Interactions:
Avoid alcohol.
Avoid milk, calcium containing dairy products, iron, antacids, or aluminum salts 2 hours before or 6 hours after using antacids while on this medication.
Take with food.

# GenBank_ID:
Not Available

# Generic_Name:
Ketoconazole

# HET_ID:
KTN

# Half_Life:
2 hours

# InChI_Identifier:
InChI=1S/C26H28Cl2N4O4/c1-19(33)31-10-12-32(13-11-31)21-3-5-22(6-4-21)34-15-23-16-35-26(36-23,17-30-9-8-29-18-30)24-7-2-20(27)14-25(24)28/h2-9,14,18,23H,10-13,15-17H2,1H3

# InChI_Key:
InChIKey=XMAYWYJOQHXEEK-UHFFFAOYSA-N

# Indication:
For the treatment of the following systemic fungal infections: candidiasis, chronic mucocutaneous candidiasis, oral thrush, candiduria, blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis.

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
D00351

# LIMS_Drug_ID:
1026

# Mechanism_Of_Action:
Ketoconazole interacts with 14-&alpha; demethylase, a cytochrome P-450 enzyme necessary for the conversion of lanosterol to ergosterol. This results in inhibition of ergosterol synthesis and increased fungal cellular permeability. Other mechanisms may involve the inhibition of endogenous respiration, interaction with membrane phospholipids, inhibition of yeast transformation to mycelial forms, inhibition of purine uptake, and impairment of triglyceride and/or phospholipid biosynthesis. Ketoconazole can also inhibit the synthesis of thromboxane and sterols such as aldosterone, cortisol, and testosterone.

# Melting_Point:
146 Â°C

# Molecular_Weight_Avg:
531.431

# Molecular_Weight_Mono:
530.148760818

# Organisms_Affected:
Fungi

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/niz1297.shtml

# Pathways:
Not Available

# PharmGKB_ID:
PA450146

# Pharmacology:
Ketoconazole, like clotrimazole, fluconazole, itraconazole, and miconazole, is an imidazole antifungal agent.

# Predicted_LogP_Hydrophobicity:
4.3

# Predicted_LogS:
-4.8

# Predicted_Water_Solubility:
9.31e-03 g/l

# Primary_Accession_No:
DB01026

# Protein_Binding:
99% (in vitro, plasma protein binding)

# PubChem_Compound_ID:
Not Available

# PubChem_Substance_ID:
Not Available

# RxList_Link:
http://www.rxlist.com/cgi/generic/ketocon.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD00401

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
2%
Ketocanazole
Ketoconazol
Ketoconazol [INN-Spanish]
Ketoconazole [Usan:Ban:Inn:Jan]
Ketoconazolum [INN-Latin]

# Synthesis_Reference:
Not Available

# Toxicity:
Hepatotoxicity, LD<sub>50</sub>=86 mg/kg (orally in rat)

# Update_Date:
2013-02-08 16:19:50 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Ketoconazole

# pKa_Isoelectric_Point:
Not Available

# Phase_1_Metabolizing_Enzyme_10_Gene_Name:
CYP2A6

# Phase_1_Metabolizing_Enzyme_10_ID:
5718

# Phase_1_Metabolizing_Enzyme_10_Name:
Cytochrome P450 2A6

# Phase_1_Metabolizing_Enzyme_10_Protein_Sequence:
>Cytochrome P450 2A6
MLASGMLLVALLVCLTVMVLMSVWQQRKSKGKLPPGPTPLPFIGNYLQLNTEQMYNSLMK
ISERYGPVFTIHLGPRRVVVLCGHDAVREALVDQAEEFSGRGEQATFDWVFKGYGVVFSN
GERAKQLRRFSIATLRDFGVGKRGIEERIQEEAGFLIDAHRGTGGANIDPTFFLSRTVSN
VISSIVFGDRFDYKDKEFLSLLRMMLGIFQFTSTSTGQLYEMFSSVMKHLPGPQQQAFQL
LQGLEDFIAKKVEHNQRTLDPNSPRDFIDSFLIRMQEEEKNPNTEFYLKNLVMTTLNLFI
GGTETVSTTLRYGFLLLMKHPEVEAKVHEEIDRVIGKNRQPKFEDRAKMPYMEAVIHEIQ
RFGDVIPMSLARRVKKDTKFRDFFLPKGTEVYPMLGSVLRDPSFFSNPQDFNPQHFLNEK
GQFKKSDAFVPFSIGKRNCFGEGLARMELFLFFTTVMQNFRLKSSQSPKDIDVSPKHVGF
ATIPRNYTMSFLPR

# Phase_1_Metabolizing_Enzyme_10_SwissProt_ID:
P11509

# Phase_1_Metabolizing_Enzyme_11_Gene_Name:
CYP26A1

# Phase_1_Metabolizing_Enzyme_11_ID:
5934

# Phase_1_Metabolizing_Enzyme_11_Name:
Cytochrome P450 26A1

# Phase_1_Metabolizing_Enzyme_11_Protein_Sequence:
>Cytochrome P450 26A1
MGLPALLASALCTFVLPLLLFLAAIKLWDLYCVSGRDRSCALPLPPGTMGFPFFGETLQM
VLQRRKFLQMKRRKYGFIYKTHLFGRPTVRVMGADNVRRILLGDDRLVSVHWPASVRTIL
GSGCLSNLHDSSHKQRKKVIMRAFSREALECYVPVITEEVGSSLEQWLSCGERGLLVYPE
VKRLMFRIAMRILLGCEPQLAGDGDSEQQLVEAFEEMTRNLFSLPIDVPFSGLYRGMKAR
NLIHARIEQNIRAKICGLRASEAGQGCKDALQLLIEHSWERGERLDMQALKQSSTELLFG
GHETTASAATSLITYLGLYPHVLQKVREELKSKGLLCKSNQDNKLDMEILEQLKYIGCVI
KETLRLNPPVPGGFRVALKTFELNGYQIPKGWNVIYSICDTHDVAEIFTNKEEFNPDRFM
LPHPEDASRFSFIPFGGGLRSCVGKEFAKILLKIFTVELARHCDWQLLNGPPTMKTSPTV
YPVDNLPARFTHFHGEI

# Phase_1_Metabolizing_Enzyme_11_SwissProt_ID:
O43174

# Phase_1_Metabolizing_Enzyme_12_Gene_Name:
CYP2C19

# Phase_1_Metabolizing_Enzyme_12_ID:
6016

# Phase_1_Metabolizing_Enzyme_12_Name:
Cytochrome P450 2C19

# Phase_1_Metabolizing_Enzyme_12_Protein_Sequence:
>Cytochrome P450 2C19
MDPFVVLVLCLSCLLLLSIWRQSSGRGKLPPGPTPLPVIGNILQIDIKDVSKSLTNLSKI
YGPVFTLYFGLERMVVLHGYEVVKEALIDLGEEFSGRGHFPLAERANRGFGIVFSNGKRW
KEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVICS
IIFQKRFDYKDQQFLNLMEKLNENIRIVSTPWIQICNNFPTIIDYFPGTHNKLLKNLAFM
ESDILEKVKEHQESMDINNPRDFIDCFLIKMEKEKQNQQSEFTIENLVITAADLLGAGTE
TTSTTLRYALLLLLKHPEVTAKVQEEIERVVGRNRSPCMQDRGHMPYTDAVVHEVQRYID
LIPTSLPHAVTCDVKFRNYLIPKGTTILTSLTSVLHDNKEFPNPEMFDPRHFLDEGGNFK
KSNYFMPFSAGKRICVGEGLARMELFLFLTFILQNFNLKSLIDPKDLDTTPVVNGFASVP
PFYQLCFIPV

# Phase_1_Metabolizing_Enzyme_12_SwissProt_ID:
P33261

# Phase_1_Metabolizing_Enzyme_13_Gene_Name:
CYP11A1

# Phase_1_Metabolizing_Enzyme_13_ID:
6017

# Phase_1_Metabolizing_Enzyme_13_Name:
Cholesterol side-chain cleavage enzyme, mitochondrial

# Phase_1_Metabolizing_Enzyme_13_Protein_Sequence:
>Cholesterol side-chain cleavage enzyme, mitochondrial
MLAKGLPPRSVLVKGCQTFLSAPREGLGRLRVPTGEGAGISTRSPRPFNEIPSPGDNGWL
NLYHFWRETGTHKVHLHHVQNFQKYGPIYREKLGNVESVYVIDPEDVALLFKSEGPNPER
FLIPPWVAYHQYYQRPIGVLLKKSAAWKKDRVALNQEVMAPEATKNFLPLLDAVSRDFVS
VLHRRIKKAGSGNYSGDISDDLFRFAFESITNVIFGERQGMLEEVVNPEAQRFIDAIYQM
FHTSVPMLNLPPDLFRLFRTKTWKDHVAAWDVIFSKADIYTQNFYWELRQKGSVHHDYRG
ILYRLLGDSKMSFEDIKANVTEMLAGGVDTTSMTLQWHLYEMARNLKVQDMLRAEVLAAR
HQAQGDMATMLQLVPLLKASIKETLRLHPISVTLQRYLVNDLVLRDYMIPAKTLVQVAIY
ALGREPTFFFDPENFDPTRWLSKDKNITYFRNLGFGWGVRQCLGRRIAELEMTIFLINML
ENFRVEIQHLSDVGTTFNLILMPEKPISFTFWPFNQEATQQ

# Phase_1_Metabolizing_Enzyme_13_SwissProt_ID:
P05108

# Phase_1_Metabolizing_Enzyme_14_Gene_Name:
CYP1A1

# Phase_1_Metabolizing_Enzyme_14_ID:
6024

# Phase_1_Metabolizing_Enzyme_14_Name:
Cytochrome P450 1A1

# Phase_1_Metabolizing_Enzyme_14_Protein_Sequence:
>Cytochrome P450 1A1
MLFPISMSATEFLLASVIFCLVFWVIRASRPQVPKGLKNPPGPWGWPLIGHMLTLGKNPH
LALSRMSQQYGDVLQIRIGSTPVVVLSGLDTIRQALVRQGDDFKGRPDLYTFTLISNGQS
MSFSPDSGPVWAARRRLAQNGLKSFSIASDPASSTSCYLEEHVSKEAEVLISTLQELMAG
PGHFNPYRYVVVSVTNVICAICFGRRYDHNHQELLSLVNLNNNFGEVVGSGNPADFIPIL
RYLPNPSLNAFKDLNEKFYSFMQKMVKEHYKTFEKGHIRDITDSLIEHCQEKQLDENANV
QLSDEKIINIVLDLFGAGFDTVTTAISWSLMYLVMNPRVQRKIQEELDTVIGRSRRPRLS
DRSHLPYMEAFILETFRHSSFVPFTIPHSTTRDTSLKGFYIPKGRCVFVNQWQINHDQKL
WVNPSEFLPERFLTPDGAIDKVLSEKVIIFGMGKRKCIGETIARWEVFLFLAILLQRVEF
SVPLGVKVDMTPIYGLTMKHACCEHFQMQLRS

# Phase_1_Metabolizing_Enzyme_14_SwissProt_ID:
P04798

# Phase_1_Metabolizing_Enzyme_15_Gene_Name:
CYP2B6

# Phase_1_Metabolizing_Enzyme_15_ID:
6030

# Phase_1_Metabolizing_Enzyme_15_Name:
Cytochrome P450 2B6

# Phase_1_Metabolizing_Enzyme_15_Protein_Sequence:
>Cytochrome P450 2B6
MELSVLLFLALLTGLLLLLVQRHPNTHDRLPPGPRPLPLLGNLLQMDRRGLLKSFLRFRE
KYGDVFTVHLGPRPVVMLCGVEAIREALVDKAEAFSGRGKIAMVDPFFRGYGVIFANGNR
WKVLRRFSVTTMRDFGMGKRSVEERIQEEAQCLIEELRKSKGALMDPTFLFQSITANIIC
SIVFGKRFHYQDQEFLKMLNLFYQTFSLISSVFGQLFELFSGFLKYFPGAHRQVYKNLQE
INAYIGHSVEKHRETLDPSAPKDLIDTYLLHMEKEKSNAHSEFSHQNLNLNTLSLFFAGT
ETTSTTLRYGFLLMLKYPHVAERVYREIEQVIGPHRPPELHDRAKMPYTEAVIYEIQRFS
DLLPMGVPHIVTQHTSFRGYIIPKDTEVFLILSTALHDPHYFEKPDAFNPDHFLDANGAL
KKTEAFIPFSLGKRICLGEGIARAELFLFFTTILQNFSMASPVAPEDIDLTPQECGVGKI
PPTYQIRFLPR

# Phase_1_Metabolizing_Enzyme_15_SwissProt_ID:
P20813

# Phase_1_Metabolizing_Enzyme_16_Gene_Name:
CYP3A7

# Phase_1_Metabolizing_Enzyme_16_ID:
6107

# Phase_1_Metabolizing_Enzyme_16_Name:
Cytochrome P450 3A7

# Phase_1_Metabolizing_Enzyme_16_Protein_Sequence:
>Cytochrome P450 3A7
MDLIPNLAVETWLLLAVSLILLYLYGTRTHGLFKKLGIPGPTPLPFLGNALSFRKGYWTF
DMECYKKYRKVWGIYDCQQPMLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKNAISI
AEDEEWKRIRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKHVFGAYS
MDVITSTSFGVSIDSLNNPQDPFVENTKKLLRFNPLDPFVLSIKVFPFLTPILEALNITV
FPRKVISFLTKSVKQIKEGRLKETQKHRVDFLQLMIDSQNSKDSETHKALSDLELMAQSI
IFIFAGYETTSSVLSFIIYELATHPDVQQKVQKEIDTVLPNKAPPTYDTVLQLEYLDMVV
NETLRLFPVAMRLERVCKKDVEINGMFIPKGVVVMIPSYVLHHDPKYWREPEKFLPERFS
KKNKDNIDPYIYTPFGSGPRNCIGMRFALVNMKLALVRVLQNFSFKPCKETQIPLKLRFG
GLLLTEKPIVLKAESRDETVSGA

# Phase_1_Metabolizing_Enzyme_16_SwissProt_ID:
P24462

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
CYP11B1

# Phase_1_Metabolizing_Enzyme_1_ID:
805

# Phase_1_Metabolizing_Enzyme_1_Name:
Cytochrome P450 11B1, mitochondrial

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Cytochrome P450 11B1, mitochondrial precursor
MALRAKAEVCMAVPWLSLQRAQALGTRAARVPRTVLPFEAMPQRPGNRWLRLLQIWREQG
YEDLHLEVHQTFQELGPIFRYDLGGAGMVCVMLPEDVEKLQQVDSLHPHRMSLEPWVAYR
QHRGHKCGVFLLNGPEWRFNRLRLNPEVLSPNAVQRFLPMVDAVARDFSQALKKKVLQNA
RGSLTLDVQPSIFHYTIEASNLALFGERLGLVGHSPSSASLNFLHALEVMFKSTVQLMFM
PRSLSRWTSPKVWKEHFEAWDCIFQYGDNCIQKIYQELAFSRPQQYTSIVAELLLNAELS
PDAIKANSMELTAGSVDTTVFPLLMTLFELARNPNVQQALRQESLAAAASISEHPQKATT
ELPLLRAALKETLRLYPVGLFLERVVSSDLVLQNYHIPAGTLVRVFLYSLGRNPALFPRP
ERYNPQRWLDIRGSGRNFYHVPFGFGMRQCLGRRLAEAEMLLLLHHVLKHLQVETLTQED
IKMVYSFILRPSMCPLLTFRAIN

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P15538

# Phase_1_Metabolizing_Enzyme_2_Gene_Name:
CYP51A1

# Phase_1_Metabolizing_Enzyme_2_ID:
1010

# Phase_1_Metabolizing_Enzyme_2_Name:
Cytochrome P450 51A1

# Phase_1_Metabolizing_Enzyme_2_Protein_Sequence:
>Cytochrome P450 51A1
MLLLGLLQAGGSVLGQAMEKVTGGNLLSMLLIACAFTLSLVYLIRLAAGHLVQLPAGVKS
PPYIFSPIPFLGHAIAFGKSPIEFLENAYEKYGPVFSFTMVGKTFTYLLGSDAAALLFNS
KNEDLNAEDVYSRLTTPVFGKGVAYDVPNPVFLEQKKMLKSGLNIAHFKQHVSIIEKETK
EYFESWGESGEKNVFEALSELIILTASHCLHGKEIRSQLNEKVAQLYADLDGGFSHAAWL
LPGWLPLPSFRRRDRAHREIKDIFYKAIQKRRQSQEKIDDILQTLLDATYKDGRPLTDDE
VAGMLIGLLLAGQHTSSTTSAWMGFFLARDKTLQKKCYLEQKTVCGENLPPLTYDQLKDL
NLLDRCIKETLRLRPPIMIMMRMARTPQTVAGYTIPPGHQVCVSPTVNQRLKDSWVERLD
FNPDRYLQDNPASGEKFAYVPFGAGRHRCIGENFAYVQIKTIWSTMLRLYEFDLIDGYFP
TVNYTTMIHTPENPVIRYKRRSK

# Phase_1_Metabolizing_Enzyme_2_SwissProt_ID:
Q16850

# Phase_1_Metabolizing_Enzyme_3_Gene_Name:
CYP1B1

# Phase_1_Metabolizing_Enzyme_3_ID:
1898

# Phase_1_Metabolizing_Enzyme_3_Name:
Cytochrome P450 1B1

# Phase_1_Metabolizing_Enzyme_3_Protein_Sequence:
>Cytochrome P450 1B1
MGTSLSPNDPWPLNPLSIQQTTLLLLLSVLATVHVGQRLLRQRRRQLRSAPPGPFAWPLI
GNAAAVGQAAHLSFARLARRYGDVFQIRLGSCPIVVLNGERAIHQALVQQGSAFADRPAF
ASFRVVSGGRSMAFGHYSEHWKVQRRAAHSMMRNFFTRQPRSRQVLEGHVLSEARELVAL
LVRGSADGAFLDPRPLTVVAVANVMSAVCFGCRYSHDDPEFRELLSHNEEFGRTVGAGSL
VDVMPWLQYFPNPVRTVFREFEQLNRNFSNFILDKFLRHCESLRPGAAPRDMMDAFILSA
EKKAAGDSHGGGARLDLENVPATITDIFGASQDTLSTALQWLLLLFTRYPDVQTRVQAEL
DQVVGRDRLPCMGDQPNLPYVLAFLYEAMRFSSFVPVTIPHATTANTSVLGYHIPKDTVV
FVNQWSVNHDPLKWPNPENFDPARFLDKDGLINKDLTSRVMIFSVGKRRCIGEELSKMQL
FLFISILAHQCDFRANPNEPAKMNFSYGLTIKPKSFKVNVTLRESMELLDSAVQNLQAKE
TCQ

# Phase_1_Metabolizing_Enzyme_3_SwissProt_ID:
Q16678

# Phase_1_Metabolizing_Enzyme_4_Gene_Name:
CYP3A5

# Phase_1_Metabolizing_Enzyme_4_ID:
4118

# Phase_1_Metabolizing_Enzyme_4_Name:
Cytochrome P450 3A5

# Phase_1_Metabolizing_Enzyme_4_Protein_Sequence:
>Cytochrome P450 3A5
MDLIPNLAVETWLLLAVSLVLLYLYGTRTHGLFKRLGIPGPTPLPLLGNVLSYRQGLWKF
DTECYKKYGKMWGTYEGQLPVLAITDPDVIRTVLVKECYSVFTNRRSLGPVGFMKSAISL
AEDEEWKRIRSLLSPTFTSGKLKEMFPIIAQYGDVLVRNLRREAEKGKPVTLKDIFGAYS
MDVITGTSFGVNIDSLNNPQDPFVESTKKFLKFGFLDPLFLSIILFPFLTPVFEALNVSL
FPKDTINFLSKSVNRMKKSRLNDKQKHRLDFLQLMIDSQNSKETESHKALSDLELAAQSI
IFIFAGYETTSSVLSFTLYELATHPDVQQKLQKEIDAVLPNKAPPTYDAVVQMEYLDMVV
NETLRLFPVAIRLERTCKKDVEINGVFIPKGSMVVIPTYALHHDPKYWTEPEEFRPERFS
KKKDSIDPYIYTPFGTGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLDTQG
LLQPEKPIVLKVDSRDGTLSGE

# Phase_1_Metabolizing_Enzyme_4_SwissProt_ID:
P20815

# Phase_1_Metabolizing_Enzyme_5_Gene_Name:
CYP2D6

# Phase_1_Metabolizing_Enzyme_5_ID:
4119

# Phase_1_Metabolizing_Enzyme_5_Name:
Cytochrome P450 2D6

# Phase_1_Metabolizing_Enzyme_5_Protein_Sequence:
>Cytochrome P450 2D6
MGLEALVPLAVIVAIFLLLVDLMHRRQRWAARYPPGPLPLPGLGNLLHVDFQNTPYCFDQ
LRRRFGDVFSLQLAWTPVVVLNGLAAVREALVTHGEDTADRPPVPITQILGFGPRSQGVF
LARYGPAWREQRRFSVSTLRNLGLGKKSLEQWVTEEAACLCAAFANHSGRPFRPNGLLDK
AVSNVIASLTCGRRFEYDDPRFLRLLDLAQEGLKEESGFLREVLNAVPVLLHIPALAGKV
LRFQKAFLTQLDELLTEHRMTWDPAQPPRDLTEAFLAEMEKAKGNPESSFNDENLRIVVA
DLFSAGMVTTSTTLAWGLLLMILHPDVQRRVQQEIDDVIGQVRRPEMGDQAHMPYTTAVI
HEVQRFGDIVPLGVTHMTSRDIEVQGFRIPKGTTLITNLSSVLKDEAVWEKPFRFHPEHF
LDAQGHFVKPEAFLPFSAGRRACLGEPLARMELFLFFTSLLQHFSFSVPTGQPRPSHHGV
FAFLVSPSPYELCAVPR

# Phase_1_Metabolizing_Enzyme_5_SwissProt_ID:
P10635

# Phase_1_Metabolizing_Enzyme_6_Gene_Name:
CYP1A2

# Phase_1_Metabolizing_Enzyme_6_ID:
4200

# Phase_1_Metabolizing_Enzyme_6_Name:
Cytochrome P450 1A2

# Phase_1_Metabolizing_Enzyme_6_Protein_Sequence:
>Cytochrome P450 1A2
MALSQSVPFSATELLLASAIFCLVFWVLKGLRPRVPKGLKSPPEPWGWPLLGHVLTLGKN
PHLALSRMSQRYGDVLQIRIGSTPVLVLSRLDTIRQALVRQGDDFKGRPDLYTSTLITDG
QSLTFSTDSGPVWAARRRLAQNALNTFSIASDPASSSSCYLEEHVSKEAKALISRLQELM
AGPGHFDPYNQVVVSVANVIGAMCFGQHFPESSDEMLSLVKNTHEFVETASSGNPLDFFP
ILRYLPNPALQRFKAFNQRFLWFLQKTVQEHYQDFDKNSVRDITGALFKHSKKGPRASGN
LIPQEKIVNLVNDIFGAGFDTVTTAISWSLMYLVTKPEIQRKIQKELDTVIGRERRPRLS
DRPQLPYLEAFILETFRHSSFLPFTIPHSTTRDTTLNGFYIPKKCCVFVNQWQVNHDPEL
WEDPSEFRPERFLTADGTAINKPLSEKMMLFGMGKRRCIGEVLAKWEIFLFLAILLQQLE
FSVPPGVKVDLTPIYGLTMKHARCEHVQARRFSIN

# Phase_1_Metabolizing_Enzyme_6_SwissProt_ID:
P05177

# Phase_1_Metabolizing_Enzyme_7_Gene_Name:
CYP3A4

# Phase_1_Metabolizing_Enzyme_7_ID:
4512

# Phase_1_Metabolizing_Enzyme_7_Name:
Cytochrome P450 3A4

# Phase_1_Metabolizing_Enzyme_7_Protein_Sequence:
>Cytochrome P450 3A4
MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMF
DMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISI
AEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYS
MDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICV
FPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSI
IFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVV
NETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFS
KKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLG
GLLQPEKPVVLKVESRDGTVSGA

# Phase_1_Metabolizing_Enzyme_7_SwissProt_ID:
P08684

# Phase_1_Metabolizing_Enzyme_8_Gene_Name:
CYP2C9

# Phase_1_Metabolizing_Enzyme_8_ID:
4757

# Phase_1_Metabolizing_Enzyme_8_Name:
Cytochrome P450 2C9

# Phase_1_Metabolizing_Enzyme_8_Protein_Sequence:
>Cytochrome P450 2C9
MDSLVVLVLCLSCLLLLSLWRQSSGRGKLPPGPTPLPVIGNILQIGIKDISKSLTNLSKV
YGPVFTLYFGLKPIVVLHGYEAVKEALIDLGEEFSGRGIFPLAERANRGFGIVFSNGKKW
KEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVICS
IIFHKRFDYKDQQFLNLMEKLNENIKILSSPWIQICNNFSPIIDYFPGTHNKLLKNVAFM
KSYILEKVKEHQESMDMNNPQDFIDCFLMKMEKEKHNQPSEFTIESLENTAVDLFGAGTE
TTSTTLRYALLLLLKHPEVTAKVQEEIERVIGRNRSPCMQDRSHMPYTDAVVHEVQRYID
LLPTSLPHAVTCDIKFRNYLIPKGTTILISLTSVLHDNKEFPNPEMFDPHHFLDEGGNFK
KSKYFMPFSAGKRICVGEALAGMELFLFLTSILQNFNLKSLVDPKNLDTTPVVNGFASVP
PFYQLCFIPV

# Phase_1_Metabolizing_Enzyme_8_SwissProt_ID:
P11712

# Phase_1_Metabolizing_Enzyme_9_Gene_Name:
CYP2C8

# Phase_1_Metabolizing_Enzyme_9_ID:
4924

# Phase_1_Metabolizing_Enzyme_9_Name:
Cytochrome P450 2C8

# Phase_1_Metabolizing_Enzyme_9_Protein_Sequence:
>Cytochrome P450 2C8
MEPFVVLVLCLSFMLLFSLWRQSCRRRKLPPGPTPLPIIGNMLQIDVKDICKSFTNFSKV
YGPVFTVYFGMNPIVVFHGYEAVKEALIDNGEEFSGRGNSPISQRITKGLGIISSNGKRW
KEIRRFSLTTLRNFGMGKRSIEDRVQEEAHCLVEELRKTKASPCDPTFILGCAPCNVICS
VVFQKRFDYKDQNFLTLMKRFNENFRILNSPWIQVCNNFPLLIDCFPGTHNKVLKNVALT
RSYIREKVKEHQASLDVNNPRDFIDCFLIKMEQEKDNQKSEFNIENLVGTVADLFVAGTE
TTSTTLRYGLLLLLKHPEVTAKVQEEIDHVIGRHRSPCMQDRSHMPYTDAVVHEIQRYSD
LVPTGVPHAVTTDTKFRNYLIPKGTTIMALLTSVLHDDKEFPNPNIFDPGHFLDKNGNFK
KSDYFMPFSAGKRICAGEGLARMELFLFLTTILQNFNLKSVDDLKNLNTTAVTKGIVSLP
PSYQICFIPV

# Phase_1_Metabolizing_Enzyme_9_SwissProt_ID:
P10632

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
1627190	Agut J, Palacin C, Sacristan A, Ortiz JA: Inhibition of ergosterol synthesis by sertaconazole in Candida albicans. Arzneimittelforschung. 1992 May;42(5A):718-20.
1627191	Agut J, Palacin C, Salgado J, Casas E, Sacristan A, Ortiz JA: Direct membrane-damaging effect of sertaconazole on Candida albicans as a mechanism of its fungicidal activity. Arzneimittelforschung. 1992 May;42(5A):721-4.
16375669	Borgers M, Degreef H, Cauwenbergh G: Fungal infections of the skin: infection process and antimycotic therapy. Curr Drug Targets. 2005 Dec;6(8):849-62.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
19275277	Croxtall JD, Plosker GL: Sertaconazole: a review of its use in the management of superficial mycoses in dermatology and gynaecology. Drugs. 2009;69(3):339-59.
20625155	Warrilow AG, Martel CM, Parker JE, Melo N, Lamb DC, Nes WD, Kelly DE, Kelly SL: Azole binding properties of Candida albicans sterol 14-alpha demethylase (CaCYP51). Antimicrob Agents Chemother. 2010 Oct;54(10):4235-45. Epub 2010 Jul 12.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
X13296

# Drug_Target_1_GenBank_ID_Protein:
578119

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
ERG11

# Drug_Target_1_Gene_Sequence:
>1587 bp
ATGGCTATTGTTGAAACTGTCATTGATGGCATTAATTATTTTTTGTCCCTTAGTGTTACA
CAACAGATCAGTATATTATTAGGGGTTCCATTTGTTTACAACTTAGTATGGCAATATTTA
TATTCATTAAGAAAAGATAGAGCTCCATTAGTGTTTTATTGGATTCCTTGGTTTGGTTCT
GCAGCTTCATATGGTCAACAACCTTATGAATTTTTCGAATCATGTCGTCAAAAGTATGGT
GATGTATTTTCATTTATGTTATTAGGGAAAATTATGACGGTTTATTTAGGTCCAAAAGGT
CATGAATTTGTTTTTAATGCTAAATTATCTGATGTTTCTGCTGAAGATGCTTATAAACAT
TTAACTACTCCAGTTTTCGGTAAAGGGGTTATTTATGATTGTCCAAATTCCAGATTAATG
GAACAAAAAAAATTTGCTAAATTTGCTTTGACTACTGATTCATTTAAAAGATATGTTCCT
AAGATTAGAGAAGAAATTTTGAATTATTTTGTTACTGATGAAAGTTTCAAATTGAAAGAA
AAAACTCATGGGGTTGCCAATGTTATGAAAACTCAACCAGAAATTACTATTTTCACTGCT
TCAAGATCTTTATTTGGTGATGAAATGAGAAGAATTTTTGACCGTTCATTTGCTCAACTA
TATTCTGATTTAGATAAAGGTTTTACCCCTATTAATTTTGTTTTCCCTAATTTACCTTTA
CCTCATTATTGGAGACGTGATGCTGCTCAAAAGAAAATCTCTGCTACTTATATGAAAGAA
ATTAAACTGAGAAGAGAACGTGGTGATATTGATCCAAATCGTGATTTAATTGATTCCTTA
TTGATTCATTCAACTTATAAAGATGGTGTGAAAATGACTGATCAAGAAATTGCTAATCTT
TTAATTGGTATTCTTATGGGTGGTCAACATACTTCTGCTTCTACTTCTGCTTGGTTCTTG
TTACATTTAGGTGAAAAACCTCATTTACAAGATGTTATTTATCAAGAAGTTGTTGAATTA
TTGAAAGAAAAAGGTGGTGATTTGAATGATTTGACTTATGAAGATTTACAAAAATTACCA
TCAGTCAATAACACTATTAAGGAAACTCTCAGAATGCATATGCCATTACATTCTATTTTT
AGAAAAGTTACTAACCCATTAAGAATCCCTGAAACCAATTATATTGTTCCAAAAGGTCAT
TATGTTTTAGTTTCTCCAGGTTATGCTCATACTAGTGAAAGATATTTTGATAACCCTGAA
GATTTTGATCCAACTAGATGGGATACTGCTGCTGCCAAAGCTAATTCTGTTTCATTTAAC
TCTTCTGATGAAGTTGATTATGGGTTTGGGAAAGTTTCTAAAGGGGTTTCTTCACCTTAT
TTACCATTTGGTGGTGGTAGACATAGATGTATTGGGGAACAATTTGCTTATGTTCAATTA
GGAACCATTTTAACTACTTTTGTTTATAATTTAAGATGGACTATTGATGGTTATAAAGTG
CCTGACCCTGATTATAGTTCAATGGTGGTTTTACCTACTGAACCAGCAGAAATCATTTGG
GAAAAAAGAGAAACTTGTATGTTTTAA

# Drug_Target_1_General_Function:
Secondary metabolites biosynthesis, transport and catabolism

# Drug_Target_1_General_References:
2644625	Lai MH, Kirsch DR: Nucleotide sequence of cytochrome P450 L1A1 (lanosterol 14 alpha-demethylase) from Candida albicans. Nucleic Acids Res. 1989 Jan 25;17(2):804.
7819160	Boscott PE, Grant GH: Modeling cytochrome P450 14 alpha demethylase (Candida albicans) from P450cam. J Mol Graph. 1994 Sep;12(3):185-92, 195.
9210671	White TC: The presence of an R467K amino acid substitution and loss of allelic variation correlate with an azole-resistant lanosterol 14alpha demethylase in Candida albicans. Antimicrob Agents Chemother. 1997 Jul;41(7):1488-94.
9228762	Loffler J, Kelly SL, Hebart H, Schumacher U, Lass-Florl C, Einsele H: Molecular analysis of cyp51 from fluconazole-resistant Candida albicans strains. FEMS Microbiol Lett. 1997 Jun 15;151(2):263-8.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
260

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
60676

# Drug_Target_1_Name:
Cytochrome P450 51

# Drug_Target_1_Number_of_Residues:
528

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00067	p450

# Drug_Target_1_Protein_Sequence:
>Cytochrome P450 51
MAIVETVIDGINYFLSLSVTQQISILLGVPFVYNLVWQYLYSLRKDRAPLVFYWIPWFGS
AASYGQQPYEFFESCRQKYGDVFSFMLLGKIMTVYLGPKGHEFVFNAKLSDVSAEDAYKH
LTTPVFGKGVIYDCPNSRLMEQKKFAKFALTTDSFKRYVPKIREEILNYFVTDESFKLKE
KTHGVANVMKTQPEITIFTASRSLFGDEMRRIFDRSFAQLYSDLDKGFTPINFVFPNLPL
PHYWRRDAAQKKISATYMKEIKSRRERGDIDPNRDLIDSLLIHSTYKDGVKMTDQEIANL
LIGILMGGQHTSASTSAWFLLHLGEKPHLQDVIYQEVVELLKEKGGDLNDLTYEDLQKLP
SVNNTIKETLRMHMPLHSIFRKVTNPLRIPETNYIVPKGHYVLVSPGYAHTSERYFDNPE
DFDPTRWDTAAAKANSVSFNSSDEVDYGFGKVSKGVSSPYLPFGGGRHRCIGEQFAYVQL
GTILTTFVYNLRWTIDGYKVPDPDYSSMVVLPTEPAEIIWEKRETCMF

# Drug_Target_1_Reaction:
obtusifoliol + 3 O2 + 3 NADPH + 3 H+ = 4alpha-methyl-5alpha-ergosta-8,14,24(28)-trien-3beta-ol + formate + 3 NADP+ + 4 H2O

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Catalyzes C14-demethylation of lanosterol which is critical for ergosterol biosynthesis. It transforms lanosterol into 4,4'-dimethyl cholesta-8,14,24-triene-3-beta-ol

# Drug_Target_1_SwissProt_ID:
P10613

# Drug_Target_1_SwissProt_Name:
CP51_CANAL

# Drug_Target_1_Synonyms:
CYPLI
EC 1.14.13.70
Lanosterol 14-alpha demethylase
P450-14DM
P450-LIA1
Sterol 14- alpha demethylase

# Drug_Target_1_Theoretical_pI:
7.19

# Drug_Target_1_Transmembrane_Regions:
15-37; 50-69

#END_DRUGCARD DB01026
